^
    CANCER:

    Hepatocellular Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    nivolumab
    pembrolizumab
    tislelizumab
    		0
    PD1 inhibitor
    dostarlimab-gxly
    cemiplimab-rwlc
    sintilimab
    PD1 inhibitor
    1
    Multi-tyrosine kinase inhibitor
    regorafenib
    cabozantinib tablet
    2
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    ipilimumab biosimilar (CS1002) + CS1003
    3
    mTOR inhibitor
    sirolimus
    everolimus
    4
    PD-L1 inhibitor
    durvalumab
    PD-L1 inhibitor
    BLU-554
    		5
    FGFR4 inhibitor
    ABSK011
    H3B-6527
    FGF401
    6
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    7
    STAT3 inhibitor
    TTI-101 oral
    8
    IL-27 inhibitor
    SRF388
    9
    EphB4 inhibitor
    sEphB4-HSA
    BHG712
    10
    PD1 inhibitor, FGFR4 inhibitor
    PDR001 + FGF401
    gemcitabine
    		11
    DNA synthesis inhibitor
    fludarabine oral
    bleomycin
    cisplatin
    12
    PD-L1 inhibitor, Multi-tyrosine kinase inhibitor
    atezolizumab + cabozantinib tablet
    durvalumab + cabozantinib tablet
    13
    Retinoid X receptor modulator
    bexarotene oral
    14
    JAK2 inhibitor
    AZ 960
    15
    RET inhibitor
    selpercatinib
    16
    ER-α 36 modulator
    SNG-162
    17
    SYK inhibitor
    GS-9973
    18
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + cabozantinib tablet
    19
    c-MET inhibitor
    tepotinib
    ARQ 197
    20
    Arginase replacement
    BCT-100
    21
    BET inhibitor
    GSK525762
    22
    MCL1 inhibitor
    AZD5991
    23
    DNA synthesis inhibitor, DNA cross linking agent
    oxaliplatin
    24
    ALK inhibitor
    crizotinib
    25
    PARP inhibitor
    olaparib
    26
    FGFR inhibitor
    infigratinib
    27
    IGF-1R inhibitor
    ASP7487
    28
    CXCL12 inhibitor, Farnesyl transferase inhibitor
    tipifarnib
    29
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    30
    GPC-3-targeted CAR-T immunotherapy
    CT017
    31
    VEGFR-2 inhibitor
    ramucirumab
    32
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    33
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor, AKT inhibitor
    AKT inhibitor + sorafenib
    34
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    35
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    PD1 inhibitor + lenvatinib
    pembrolizumab + lenvatinib
    36
    pan-RAF inhibitor, ERK2 inhibitor, MEK inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + BAY86-9766
    37
    PD-L1 inhibitor, VEGF-A inhibitor
    bevacizumab + atezolizumab
    bevacizumab + durvalumab
    38
    VEGF-A inhibitor, PD1 inhibitor
    sintilimab + Byvasda (bevacizumab biosimilar)
    39
    PD-L1 inhibitor, CTLA4 inhibitor
    durvalumab + tremelimumab
    40
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    41
    pan-RAF inhibitor, TGF-β1 inhibitor, Phosphotransferase inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + LY2157299
    42
    pan-RAF inhibitor, PD1 inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + tislelizumab
    43
    PD-L1 inhibitor, FGFR4 inhibitor
    sugemalimab + BLU-554
    44
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, EGFR inhibitor, c-KIT inhibitor, PDGFR α antagonist
    gefitinib + lenvatinib
    45
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    46
    PD-L1 inhibitor, GPC-3 inhibitor
    atezolizumab + RG7686
    47
    TGF-β RI kinase inhibitor, TGF-β R2 kinase inhibitor
    LY2109761
    48
    cRAF inhibitor, Multi-tyrosine kinase inhibitor
    donafenib
    49
    Alkylating agent
    OBI-3424
    D19466
    50
    Thymidylate synthase inhibitor
    5-fluorouracil
    51
    DYRK1B inhibitor
    AZ191
    52
    AMHR2 antagonist
    GM102
    53
    IGF-2 inhibitor, IGF1 inhibitor
    BI-836845
    54
    PIK3CA inhibitor, CDK4 inhibitor, CDK6 inhibitor
    palbociclib + alpelisib
    55
    PIK3CA inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
    alpelisib + CB-228
    56
    PIK3CA inhibitor
    alpelisib
    57
    mTOR inhibitor, AKT inhibitor
    capivasertib + AZD8055
    58
    CDK9 inhibitor
    KB-0742
    59
    PKMYT1 inhibitor
    RP-6306
    60
    EGFR inhibitor
    cetuximab
    61
    AXL inhibitor
    BGB324
    62
    pan-RAF inhibitor, YAP1 inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + CA3
    63
    PRKACA inhibitor
    DS89002333
    64
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, CDK4 inhibitor, CDK6 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib + ribociclib
    lenvatinib + abemaciclib
    65
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    66
    CLDN18.2-targeted antibody-drug conjugate, DNA replication inhibitor
    SOT102
    67
    CDK4 inhibitor, ARK5 inhibitor, CDK6 inhibitor
    HX301
    68
    β-catenin inhibitor, CBP inhibitor, Wnt signalling pathway inhibitor
    PRI724
    69
    HDAC inhibitor
    REC-2282
    vorinostat
    70
    pan-RAF inhibitor, EGFR inhibitor, Multi-tyrosine kinase inhibitor
    erlotinib + sorafenib
    71
    HSP90 inhibitor
    BMS-722782
    72
    TAK1 inhibitor
    NG25
    73
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    74
    JAK2 inhibitor, FLT3 inhibitor
    fedratinib
    75
    Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
    ABT 263
    76
    CDK inhibitor
    PHA 793887
    77
    AKT inhibitor
    GSK690693
    78
    PI3K inhibitor
    OP-11
    79
    c-MET-targeted antibody-drug conjugate, Microtubule inhibitor
    SHR-A1403
    80
    GPC-3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    ZW251
    81
    DNMT inhibitor
    decitabine
    82
    FGFR inhibitor, c-MET inhibitor
    WXSH0011
    83
    CDK4 inhibitor, FGFR4 inhibitor, CDK6 inhibitor
    palbociclib + H3B-6527
    84
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    85
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    86
    CDK7 inhibitor
    YPN-005
    87
    ROS1 inhibitor
    ROS1 inhibitor
    88
    PD1 inhibitor, Angiogenesis inhibitor
    PD1 inhibitor + Angiogenesis inhibitor
    89
    Immunotherapy
    Immunotherapy
    90
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    91
    T-lymphocyte cell therapy
    T-lymphocyte cell therapy
    92
    CAR-T immunotherapy
    CAR-T immunotherapy
    93
    CLDN1 inhibitor
    CLDN1 inhibitor
    94
    KRAS G12C inhibitor
    KRAS G12C inhibitor
    95
    Chemotherapy
    FOLFOX
    96
    AMPK inhibitor
    AMPK inhibitor
    No biomarker
    TMB-H
    KRAS G12S
    KRAS G12R
    KRAS G12D
    KRAS G12A
    KRAS G12C
    KRAS G12V
    KRAS Q61H
    KRAS A146T
    KRAS G13D
    PRDX1 overexpression
    PD-L1 expression
    FGF19 positive
    PD-L1 overexpression
    FGF19 overexpression
    PD-L1 underexpression
    FGF19 elevation
    FGF19-L
    FGF19 expression
    FGF19 negative
    FGF19 deletion
    RAD51AP1 overexpression
    NRAS Q61L
    NRAS Q61H
    NRAS Q61K
    NRAS Q61R
    NRAS expression
    FGF21 elevation
    GPC3 positive
    GPC3 overexpression
    GPC3 expression
    FGF21 overexpression
    AFP elevation
    NTRK3 fusion
    MSI-H/dMMR
    MET overexpression
    KDR overexpression
    KDR elevation
    FGF3 amplification
    FGFR4 expression
    FGF3 overexpression
    FGFR4 overexpression
    EFNB2 negative
    EFNB2 positive
    MET amplification
    FGFR4 deletion
    MET elevation
    MET expression
    DLAT overexpression
    NTRK2 fusion
    NTRK1 fusion
    RET fusion
    VEGFA elevation
    FGFR2 fusion
    FOXA3 overexpression
    CXCL12 elevation
    ST6GAL1 elevation
    ARID1A mutation
    ANGPT2-L
    FGFR4 G388R + NOS3 rs2070744
    miR-216a-3p overexpression
    PAK4 deletion
    CDKN2A deletion
    HOXC8 overexpression
    TGFB1 elevation
    FGF4 amplification
    ADAM9 underexpression
    KPNA3 underexpression
    PCSK9 underexpression
    ASS1 negative
    KMT2C mutation
    CD163 underexpression
    EGFR overexpression
    CTNNB1 mutation
    TNFRSF9 elevation
    ACLY underexpression
    ASF1B overexpression
    GPX2 underexpression
    ZNF207 underexpression
    KLB expression
    NAPSB overexpression
    HLA-A*24:02
    ATP7A overexpression
    SLFN11 elevation
    THBS1 expression
    ATF4 overexpression
    GOSR2 overexpression
    PDIA6 overexpression
    SRPRB overexpression
    SLC22A3 expression
    SNX7 overexpression
    TSC1 mutation
    RET amplification + TMB-H + PD-L1 expression
    POLE V1368M + ERBB3 G1271S + TNFAIP3 P714A + PRKN I69T + TSC2 G1399R + TMB-L
    FANCA Q1307fs
    SETD2 mutation + LRP1B mutation
    CTNNB1 expression
    CTNNB1 S45P
    ANGPT2 elevation
    EGFR positive
    NTRK1 mutation
    DDR
    Low PLR
    Chr amplification(11)(q23)
    FAT1 mutation + TP53 wild-type
    High NLR
    LRP1B mutation + TP53 wild-type
    Chr amplification(11)(q13)
    PDSS1 overexpression
    PUDP overexpression
    ZNF765 overexpression
    IL6 elevation
    GZMA underexpression
    HGF elevation
    HGF elevation + VEGFA elevation
    TP53 wild-type
    AKR1C3 overexpression
    APP overexpression
    TSC2 deletion
    NFE2L2 overexpression
    S100A8 overexpression
    S100A16 overexpression
    ABCC1 overexpression
    THY1 overexpression
    FGFR1 overexpression
    NFE2L2 mutation + CTNNB1 mutation
    miR-96 expression
    RNASE7 elevation
    CD133 overexpression
    miR‑506 underexpression
    KCNQ1OT1 overexpression
    PDGFRB overexpression
    CYP1A2 overexpression
    GAS7 overexpression
    GMNN overexpression
    RRM2 overexpression
    CDC20 overexpression
    SOCS1 overexpression
    GSTP1 overexpression
    HDAC1 underexpression
    DNMT3b underexpression
    DNMT3A underexpression
    DNMT1 underexpression
    FGFR overexpression + MET overexpression
    PI16 overexpression
    FGFR overexpression
    ATP5IF1 overexpression
    HER-2 H878Y
    HES1 overexpression
    TSC2 overexpression
    JAK1 S703I
    MYC amplification
    INPP4B overexpression
    ATIC deletion
    TROAP overexpression
    GPC3 positive + EGFR expression
    miR-126-3p overexpression
    AMHR2 expression
    EPAS1 overexpression
    HIF1A overexpression
    miR-27a-3p overexpression
    miR-518d-5p overexpression
    IGF2 overexpression
    VEGFB expression
    PIK3CA H1047R
    PIK3CA E545K
    TP53 mutation
    RIT1 overexpression
    RNASE7 expression
    CCNE1 amplification
    USP22 overexpression
    OPCML underexpression + AXL overexpression
    YAP1 overexpression + WWTR1 overexpression
    DNAJB1-PRKACA fusion
    RB1 expression
    RPL22L1 overexpression
    CXCL8 elevation
    CLDN18.2 expression
    MYC overexpression
    NUAK1 overexpression
    AKR1C1 overexpression
    TNFRSF1B overexpression
    SPP1 elevation
    ZNF385A overexpression
    ZNF346 overexpression
    TERT mutation
    TERT mutation + AFP elevation
    MELK overexpression